AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$GKOS

Navratil Tomas sold $251K of GKOS

Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 1,527 shares of GLAUKOS Corp (GKOS) at an average of $164.45 ($163.93–$165.60, $0.25M total) across 3 trades on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Navratil Tomas
Published Oct 7, 2026, 11:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GKOS
Bearish
medium confidence
Mentioned
$GKOS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSBearishLow
01

Why it matters

Provides new data on insider holdings and potential market impact.

02

Market read

Insider sell adds modest negative pressure to GKOS stock.

03

What to watch

Insider may be diversifying portfolio, not losing confidence in the company.

Relevance 3/10Novelty 3/10Timing: after market close

Background

SEC Form 4 filing reports insider transaction for GKOS.

Company-level read

Ticker impact

$GKOSBearishMedium confidence
Context

Chief Development Officer Navratil Tomas sold 1,527 shares of GKOS for $251K via a 10b5-1 plan on 2026-10-05.

Expected impact

likely pressure as market prices in the insider sell

Evidence & confidence

C-level officer sold shares worth $251K, suggesting possible downside despite being a routine 10b5-1 execution.

Market effects

Sector

Biotech sector could see modest bearish sentiment.

Regional

US market may see slight dip in related biotech stocks.

Global

Limited to US biotech investors.

Counterpoint

What could challenge this read

Sale may be routine 10b5-1 execution, not a red flag.

Key entities

  • person
    Navratil Tomas

    Chief Development Officer of Glaukos Corp.

  • company
    Glaukos Corp

    Biotech company listed on NASDAQ under ticker GKOS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GKOS insider trading history →

Related articles

OCT 9
$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

theglobeandmail.com3 min
OCT 9
$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

gurufocus.com2 min
OCT 9
$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

benzinga.com2 min
OCT 9
$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.

ocbj.com2 min